Malvern-based Endo has agreed to merge with Mallinckrodt in a cash and stock deal, valuing the combined pharmaceutical company at $6.7 billion, writes

Mallinckrodt and Endo, drugmakers with a shared history of bankruptcy and U.S. opioid litigation, will merge in a deal valued at nearly $7 billion to boost scale for selling their branded drugs. Endo shareholders will get $80 million in cash and own 49.

Malvern-based Endo has found a merger partner, agreeing to combine with another troubled pharmaceutical firm in a deal valued at $6.7 million.